The purpose of this study is to investigate whether patients with diabetes due to Kir6.2 mutations can be treated with sulfonylurea medication rather than insulin, and if this is the case to investigate the mechanism for sulfonylurea response.

Further study details as provided by Royal Devon and Exeter NHS Foundation Trust:

Primary Outcome Measures:

HbA1c reduction

Secondary Outcome Measures:

insulin secretory response to intravenous glucose

insulin secretory response to oral glucose

insulin secretory response to mixed meal (sustacal)

Incidence of Hypoglycemia

Estimated Enrollment:

50

Study Start Date:

January 2004

Estimated Study Completion Date:

January 2006

Eligibility

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Diabetes due to KCNJ11 (Kir6.2) mutation

Exclusion Criteria:

None

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00334711